CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
MWN-AI** Summary
China Medical System Holdings Limited (CMS) announced significant advancements with its subsidiary, Dermavon Holdings Limited, which has received licensing rights for its innovative oral JAK1 inhibitor, povorcitinib. This drug has recently been designated as a Breakthrough Therapeutic Drug by the National Medical Products Administration (NMPA) of China, geared towards treating adult patients with non-segmental vitiligo. This designation is expected to streamline the development process for povorcitinib, currently in Phase 3 clinical trials for multiple indications, including hidradenitis suppurativa and prurigo nodularis, alongside a Phase 2 trial for asthma.
Povorcitinib, distinguished by its efficacy and favorable tolerability profile in prior trials for vitiligo, looks promising, especially given the limited treatment options available for the approximately 8.2 million non-segmental vitiligo sufferers in China. The inclusion of povorcitinib in the Breakthrough Drug list could significantly accelerate its review and approval processes, aligning with CMS's commitment to addressing unmet medical needs.
Dermavon aims to leverage this momentum and potentially broaden povorcitinib’s applications to treat additional skin-related diseases in the future. If approved, povorcitinib could enhance CMS’s offerings alongside its existing products such as ILUMETRI and ruxolitinib phosphate cream, thereby providing patients with comprehensive treatment solutions.
CMS focuses on bridging pharmaceutical innovation with commercialization, particularly in specialized fields such as skin health. Continually expanding its research and development capabilities, the company looks to capture growth in emerging markets within Southeast Asia and the Middle East, reinforcing its position as a leader in innovative pharmaceuticals.
MWN-AI** Analysis
China Medical System Holdings Limited (CMS) recently made significant strides by securing licensing rights for povorcitinib, an innovative oral JAK1 inhibitor, now classified as a Breakthrough Therapeutic Drug by the NMPA. This classification could expedite the drug's development and review processes, offering a potential game changer in treating non-segmental vitiligo, a condition affecting around 8.2 million patients in China.
Investors should closely monitor CMS stock given the promising clinical results reported in trials. A Phase 2b global trial demonstrated significant improvements in repigmentation after 24 weeks of treatment. The upcoming Phase 3 trials and continuous development pipeline could enhance investor confidence.
Moreover, with the backdrop of limited treatment options for vitiligo, povorcitinib's successful market introduction could create a substantial revenue stream for CMS. The potential synergies with Dermavon’s existing portfolio, including the FDA-approved ILUMETRI and ruxolitinib phosphate cream under NDA review, can bolster market position and customer outreach, thereby maximizing profitability.
Notably, CMS's strategic licensing agreement with Incyte offers exclusive rights for the development and commercialization of povorcitinib in key markets across Greater China and Southeast Asia. This broader geographic reach provides CMS an opportunity to capture substantial market share, especially as Asian markets for innovative dermatological treatments continue to expand.
Despite these positive indicators, potential investors should remain vigilant about ongoing regulatory risks, market competition, and the challenges that often accompany drug development and commercialization. As the company prepares for an independent listing of Dermavon, monitoring the timeline and performance metrics of povorcitinib will be critical.
In conclusion, CMS represents a compelling investment opportunity within the biopharmaceutical landscape. Its innovative approach to dermatological treatments, coupled with the promising clinical data surrounding povorcitinib, positions it favorably for significant growth in the near term.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.
Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.
In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile [1] .
In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million [2] . Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.
The Product's inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.
The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference?
1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib
2. Datas are from the China Insights Consultancy (CIC) report
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
FAQ**
What strategic advantages does China Medical Sys Hldgs CHSYF have by obtaining licensing rights for povorcitinib, especially in light of the Breakthrough Therapeutic Drugs classification by the NMPA?
How does the Phase 3 clinical trial progress of povorcitinib for non-segmental vitiligo support China Medical Sys Hldgs CHSYF’s growth and product pipeline in the dermatology market?
In what ways could the potential approval of povorcitinib impact market share and competitive positioning for China Medical Sys Hldgs CHSYF in the rapidly evolving skin health segment?
What are the implications of Dermavon Holdings Limited's independent listing on the SEHK for investors in China Medical Sys Hldgs CHSYF, particularly concerning its innovative products and market expansion strategies?
**MWN-AI FAQ is based on asking OpenAI questions about China Medical Sys Hldgs (OTC: CHSYF).
NASDAQ: CHSYF
CHSYF Trading
0.0% G/L:
$1.35 Last:
1,000 Volume:
$1.35 Open:
